Mapracorat exhibits a better safety profile with regard to growth inhibition and induction of skin atrophy after long-term topical application, thymocyte apoptosis, hyperglycaemia, and hepatic tyrosine aminotransferase activity [23] in animal models. The gene discussed is TAT; the disease is skin atrophy.